TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03609996

Intervention type: DEVICE
Intervention: Panretinal Photocoagulation
Description: Laser treatment for PDR

Intervention type: DEVICE
Intervention: Panretinal Photocoagulation
Description: Laser treatment for PDR

Intervention type: DRUG
Intervention: Lucentis
Description: Intraviteral injection

Intervention type: DRUG
Intervention: Lucentis
Description: Intraviteral injection
Study: NCT03027622

Intervention type: BEHAVIORAL
Intervention: quality of life in the patients with mild pericoronitis
Description: active surviallence by OHIP-14 TR after treatment
Study: NCT02936635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tirasemtiv
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tirasemtiv
Description: Oral
Study: NCT00741975

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affect Management
Description: 12-session group intervention including affect management training as well as sexual health skills training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Health Promotion
Description: 12-session group intervention including health information on a variety of developmentally relevant health topics
Study: NCT01504152

Intervention type: BEHAVIORAL
Intervention: questionnaire
Description: The intervention is a self-administered questionnaire that is voluntarily completed by the subject. This questionnaire has been previously validated and demonstrated to be reproducible in English speaking travelers. The final version of the survey questionnaire consists of 49 questions.Patients who never traveled after HSCT will answer only eighteen questions related to their medical and HSCT history in addition to their demographics.
Study: NCT02815540

Intervention type: PROCEDURE
Group type: OTHER
Intervention: 12-Lead ECG
Description: Subjects will be monitored while on cannabidiol with a 12-Lead ECG and/or Holter monitoring
Study: NCT01929226

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETI-204
Description: Monoclonal Antibody
Study: NCT02815540

Intervention type: DRUG
Group type: OTHER
Intervention: Cannabidiol
Description: Subjects who are planning to take state dispensed medical cannabidiol, or are already taking state dispensed medical cannabidiol.
Study: NCT04259307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omapone Peri 724mL or Winuf Peri 654mL
Description: Additional intravenous nutrition of 500 kcal per day for 3 weeks
Study: NCT00973167

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-magnitude high-frequency vibration treatment
Description: Stand on a vibration platform at 35Hz, 0.3g, 20mins/day and 5 days/week
Study: NCT00090259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Description: 50-mg losartan oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan 150 mg
Description: 100-mg losartan oral tablet + 50-mg losartan oral tablet
Study: NCT03781817

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Ketamine
Description: Subject randomized to IV Ketamine arm will receive IN Normal Saline at induction. After 8 minutes subjects will receive IV Ketamine (10 mg/mL) at a dose of 1.5 mg/kg. Level of sedation will be scored at the 15 minutes from induction to determine if adequate sedation has been achieved.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Ketamine
Description: Subject randomized to IN Ketamine arm will receive IN Ketamine (100 mg/mL) at a dose of 9 mg/kg at induction. After 8 minutes subjects will receive IV Normal Saline. Level of sedation will be scored at the 15 minutes from induction to determine if adequate sedation has been achieved.
Study: NCT00939367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem Tartrate Tablets 10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 'Sanofi-Synthelabo Inc's Ambien® Tablets 10 mg
Study: NCT03361839

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: endometrial biopsy
Description: endometrial biopsy for genetic study of endometrial receptivity

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: endometrial biopsy
Description: endometrial biopsy for genetic study of endometrial receptivity
Study: NCT01800500

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smoking cessation intervention
Description: Purchase ST products using a fixed rate of product prices

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smoking cessation intervention
Description: Purchase ST products using escalating product prices

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ecigarettes
Description: Purchase ST products using escalating product prices nicotine replacement therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ecigarettes
Description: Purchase ST products using a fixed rate of product prices nicotine replacement therapy
Study: NCT02423564

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Digesta Lac

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01966185

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tutor function on
Description: The simulator-integrated tutor function with volumetric green lighting of the intended volume to be drilled.
Study: NCT04125498

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Osteopathic treatment
Description: Manual treatment that aims to release myofascial tensions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Osteopathic treatment
Description: Manual treatment that aims to release myofascial tensions

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo treatment
Description: Similar to OMT without pressure

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo treatment
Description: Similar to OMT without pressure

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-massage
Description: Women will be instructed to perform self-massage at home once a day for 5 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-massage
Description: Women will be instructed to perform self-massage at home once a day for 5 minutes.
Study: NCT00474994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Study: NCT01457690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocofersolan
Description: Administration of a daily dose of vitamin E for 4 months:50 IU/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tocopherol alpha
Description: Administration of a daily dose of vitamin E for 4 months:50 IU/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocofersolan and tocopherol alpha
Description: Administration of a single dose of vitamin E (Vitamin E water-soluble then Vitamin E conventional fat-soluble form)
Study: NCT02384980

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FES (Gait MyoElectric Stimulator)
Description: Functional Electrical Stimulation (FES) will be tested in a group of peripheral arterial disease patients using the Gait MyoElectric Stimulator. The FES device will be applied to the calf and shin muscles on both of the patients legs.
Study: NCT03755960

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: semistandardized selection of acupuncture points according to the clinical presentation of diabetic peripheral neuropathy (DPN) symptoms; 12 treatments over 8 weeks
Study: NCT03802279

Intervention type: OTHER
Intervention: Effort test
Description: Cardiac function:~Echocardiography: left ventricular ejection fraction and global longitudinal strain will be measured.~Cardiopulmonary exercise test (CPET): left ventricular stroke volume was assessed noninvasively using a thoracic bioelectrical impedance device : maximal stroke volume at the peak of effort will be considered.~Peripheral muscle function:~* CPET: Oxygen uptake (VO2) (and carbon dioxide) output are measured. The slope of the relationship (dQ/dVO2) will be calculated between cardiac output (Q) and VO2 using measurements of Q (using measure of the stroke volume by thoracic bioelectrical impedance device) and VO2 at rest as well as during submaximal and maximal exercise~* Muscle oxygenation is measured using a near-infrared spectroscopy device.~* VO2 et Q will be measured : dQ/dVO2 is high in case of oxydation defect; If Q is low because of a concommittant cardiac impairement, the DAV = VO2/Q, and DO = (Q x DAV) / (200 - DAV) will be calculated.
Study: NCT01929226

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for ETI-204
Study: NCT03231007

Intervention type: OTHER
Intervention: Questionnaire
Description: A structured questionnaire will be administered to maternity service users. Another structured questionnaire will be administered to maternity healthcare professionals, and another to Organisational Leads (e.g. Clinical Directors at each site).
Study: NCT02438423

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine
Description: Seasonal trivalent inactivated influenza vaccine FDA-approved for 2014-2015 influenza season
Study: NCT03231007

Intervention type: OTHER
Intervention: Questionnaire
Description: A structured questionnaire will be administered to maternity service users. Another structured questionnaire will be administered to maternity healthcare professionals, and another to Organisational Leads (e.g. Clinical Directors at each site).

Intervention type: OTHER
Intervention: Questionnaire
Description: A structured questionnaire will be administered to maternity service users. Another structured questionnaire will be administered to maternity healthcare professionals, and another to Organisational Leads (e.g. Clinical Directors at each site).

Intervention type: OTHER
Intervention: Questionnaire
Description: A structured questionnaire will be administered to maternity service users. Another structured questionnaire will be administered to maternity healthcare professionals, and another to Organisational Leads (e.g. Clinical Directors at each site).
Study: NCT02611726

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture
Study: NCT00670904

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacist-delivered group program for smoking cessation
Description: Participants assigned to the treatment group participated in a pharmacist-delivered program at the clinic. The six-hour program consisted of three in-person sessions delivered at 2-week intervals over 5 weeks to a small group of smokers. Participants were offered their choice of one medication either bupropion IR or nicotine patch using doses and durations based on current medical practices. Participants receiving bupropion received a quantity sufficient to complete 12 weeks of therapy. Participants receiving nicotine patches received a quantity sufficient to complete 8 weeks of step-down therapy.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Brief standard care session for smoking cessation delivered over the telephone
Description: Those assigned to the control group received one 5 to 10 minute session delivered by the clinical pharmacist over the telephone that included all the components of standard care recommended by the Clinical Practice Guidelines for brief interventions delivered by health care providers. Participants were offered their choice of one medication either bupropion IR or nicotine patch using doses and durations based on current medical practices. Participants receiving bupropion received a quantity sufficient to complete 12 weeks of therapy. Participants receiving nicotine patches received a quantity sufficient to complete 8 weeks of step-down therapy.
Study: NCT01459445

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin, Ethinylestradiol 30µg-Drospirenone
Description: Metformin: 1700 mg /day (twice per day)-6 months; EE30µg-drospirenone: 1 tb/day, 21 days/month, 6 months
Study: NCT04395807

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Helmet CPAP
Description: Start-up air flow 40 L/min. Start-up PEEP 5 cmH2O. Max PEEP 20 cmH2O. Oxygen flow / FiO2% according to 92% SpO2 target. Titrations at physician's choice.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HFNC
Description: Start-up air flow 30 L/min. Max air flow 60 L/min. Oxygen flow / FiO2% according to 92% SpO2 target. Titrations at physician's choice.
Study: NCT02438423

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02283723

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health TAPESTRY Intervention
Description: The patient will receive in-home visits from trained volunteers to assess overall health and wellness and discover any health goals patient might have. This information will be electronically communicated back to interprofessional healthcare team and used to create informed care plan, link to relevant community services and allow the patient to age optimally.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: While waiting for the Health TAPESTRY intervention, the control group will receive usual care from their healthcare providers.
Study: NCT02454023

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portable sleep monitor (ApneaLink Air)
Description: Use of a portable sleep monitor that records respiratory effort, pulse, oxygen saturation and nasal flow, and reports apneas, hypopneas, flow limitation, snoring and blood oxygen saturation in order to detect obstructive sleep apnea.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: In-laboratory polysomnography
Description: Level 1 in-laboratory polysomnography for the detection of obstructive sleep apnea.
Study: NCT01227980

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pexacerfont
Description: 300 mg, orally, once/day during week 1, 100 mg, orally, once/day during weeks 2 and 3.
Study: NCT03755960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: routine care
Description: pharmacological routine care (antidepressants, anticonvulsants, opioids, nonsteroidal antiinflammatory drugs)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: routine care
Description: pharmacological routine care (antidepressants, anticonvulsants, opioids, nonsteroidal antiinflammatory drugs)
Study: NCT01164280

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulse Rate Change
Description: Different pulse rate settings of the implantable neurostimulator
Study: NCT01227980

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 300 mg, orally, once/day during week 1, 100 mg, orally, once/day during weeks 2 and 3.
Study: NCT04318769

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AFFIRM
Description: AFFIRM is an 8-session manualized group coping skills intervention focused on reducing sexual risk behaviours and psychosocial distress among SGMY. AFFIRM is delivered by two facilitators (primarily social workers and peers) through a combination of education and rehearsal (i.e., simulation of real-life experiences) in a manner that affirms participants' sexual and gender minority identities and experiences.
Study: NCT01412164

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FIREHAWK biodegradable polymer rapamycin-eluting stent
Description: DES PCI for CAD
Study: NCT00567450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine
Description: 30ml of a mixture of ropivacaïne 0.75%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine plus mepivacaine
Description: 30ml of a mixture of ropivacaïne 0.75% associated with mepivacaïne 1.5%
Study: NCT02742831

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The intervention group will receive a 6-session intervention. The overview of the 6 sessions is as follows:~1. Behavioral chain analysis of episode where parent felt stressed with child and episode where things went well. Identification of sources of interpersonal support.~2. Stress relief techniques. Identification of short and long-term goals. Development of a detailed crisis plan.~3. Problem solving techniques.~4. Emotional regulation. Exercises to identify moods and explore connections between feelings, thoughts, and behavior.~5. Positive parenting, review of common and specific parenting challenges, child development, short and long-term effects of different discipline approaches.~6. Reflection, repeat behavioral chain analysis. Update crisis plan.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The families in the control group will be contacted by a member of the study team 6 times in 12 weeks to approximate the frequency of contact that the intervention group receives. The study team member will check in with families on the telephone or in person and will help them connect with clinic and community resources as needed.
Study: NCT00771199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Therapeutic System (TTS)-Fentanyl
Description: Participants will receive 1 transdermal patch of TTS-fentanyl containing 12 micrograms per hour (mcg/h) for 28 days. Dose can be increased or decreased as per Investigator's discretion up to 100 mcg/h.
Study: NCT03710122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Firvanq by Azurity Pharmaceuticals, Inc.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Vancomycin
Study: NCT01922713

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: white maize and a corn oil capsule
Description: \~ 0 ug RAE/d

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: orange maize and a corn oil capsule
Description: \~600 ug RAE/d

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: white maize and a vitamin A capsule
Description: 600 ug RAE/d
Study: NCT01218581

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: received oral letrozole (2.5 mg/day)and goserelin subcutaneosly (3.6 mg/month)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: received oral letrozole (2.5 mg/day)and goserelin subcutaneosly (3.6 mg/month)
Study: NCT00165672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RABEPRAZOLE SODIUM
Description: rabeprazole sodium 5 mg: once daily orally for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RABEPRAZOLE SODIUM
Description: rabeprazole sodium 10 mg: once daily orally for 4 weeks
Study: NCT00571974

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PDL-585, ScleroPLUS laser
Description: PDT Treatment; emits light with 585 nm wavelength in pulses of 1.5 milliseconds in sections of 5 mm diameter to target the lesion and surrounding tissue

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PDL-585, ScleroPLUS laser
Description: PDT Treatment; emits light with 585 nm wavelength in pulses of 1.5 milliseconds in sections of 5 mm diameter to target the lesion and surrounding tissue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Aminolevulinic Acid (Levulan KerastickTM)
Description: Topically administered; incubation time 60-180 minutes; single dose (345 mg of active 5-ALA in 1.5 ml solution); soaked onto white gauze and applied to lesion, covered with sterile Xeroform gauze

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Aminolevulinic Acid (Levulan KerastickTM)
Description: Topically administered; incubation time 60-180 minutes; single dose (345 mg of active 5-ALA in 1.5 ml solution); soaked onto white gauze and applied to lesion, covered with sterile Xeroform gauze

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluorescence Diagnosis Imaging
Description: FD Image taken prior to PDL-585 usage

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluorescence Diagnosis Imaging
Description: FD Image taken prior to PDL-585 usage
Study: NCT00893061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate
Description: Given orally
Study: NCT01105208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin suspension (Optocef, BAYO5448 )
Description: Single dose of 500 mg / 10 mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cephalexin suspension (Keflex)
Description: Single dose of 500 mg / 20 mL
Study: NCT00761761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sensoril

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02953873

Intervention type: DRUG
Group type: OTHER
Intervention: Tacrolimus Extended Release Capsule
Description: goal trough 5 - 12ng/mL
Study: NCT00851617

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Threshold® IMT
Description: The IMT group was trained using the threshold IMT device with a 40% MIP load. Each training session consisted of 5 sets with 10 breaths, twice a day
Study: NCT04632771

Intervention type: OTHER
Intervention: N/A (observational study)
Description: N/A (observational study)
Study: NCT00659451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: tablets; 50, 100 mg; od; 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: tablets; 5, 10 mg; od; 12 months
Study: NCT02762929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011A
Description: HTX-011A (bupivacaine/meloxicam), via injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Saline Placebo
Description: Saline placebo via injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011B
Description: HTX-011B (bupivacaine/meloxicam), via injection or instillation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011B
Description: HTX-011B (bupivacaine/meloxicam), via injection or instillation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011B
Description: HTX-011B (bupivacaine/meloxicam), via injection or instillation.
Study: NCT04632771

Intervention type: OTHER
Intervention: N/A (observational study)
Description: N/A (observational study)

Intervention type: OTHER
Intervention: N/A (observational study)
Description: N/A (observational study)